Paratek Pharmaceuticals, Inc.
PRTK · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 24.7% | 177.9% | 163% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 84.7% | 82.2% | 80.1% | 78.9% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -29.8% | -33.6% | -169.9% | -656.1% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -42.2% | -48.8% | -267.2% | -778.5% |
| EPS Diluted | -1.17 | -1.22 | -2.63 | -3.93 |
| % Growth | 4.1% | 53.6% | 33.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |